Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.
about
Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study.Clinical population pharmacokinetics and toxicodynamics of linezolid.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infectionsSkin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersClinical microdialysis in skin and soft tissues: an update.Linezolid for the treatment of drug-resistant infections.Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation.Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Scaling adult doses of antifungal and antibacterial agents to childrenClinical update on linezolid in the treatment of Gram-positive bacterial infections.Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression ModelsPharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.Linezolid: a new antibiotic for newborns and children?Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model.Linezolid: effectiveness and safety for approved and off-label indications.Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine modelLinezolid pharmacokinetics and pharmacodynamics in clinical treatment.Antibiotics in development targeting protein synthesis.Pharmacokinetics of linezolid in critically ill patients.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsSingle-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.Risk factors associated with high linezolid trough plasma concentrations.Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.Wide dissemination of linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent ST22 clone.Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients.Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study.Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).
P2860
Q30947691-CBF86237-38BC-4F50-91A9-363FFE3D0108Q33412422-CA2AB79A-D29C-4DE2-9545-E0403EFA1406Q33413269-CF9A7CA9-DF3B-4650-83D2-BDA9039918C9Q33657212-15CCDEA1-BFD3-4F64-BE21-DEF519782599Q33836578-1AE9354D-FD90-4B0E-B371-CCC172D11F4FQ33935469-49E0D27B-CD6F-4590-A05F-477E740D1C00Q34077052-A9D33D94-7DA6-42D7-8CA5-E07D3DBCF71AQ34618696-4D018FFF-5338-4CBE-A572-1A4E6BE4619FQ34638260-FDCCA99F-5FA8-48A0-9A59-F1F083EA627FQ34752069-EB2C04DB-D245-485A-8F25-A8A18D4C53C8Q34894133-FA3140D7-E055-409E-89F2-281613DF2712Q35191408-8F9F14DC-0955-4526-A2B5-B8D1261B677CQ35215457-C3D9B1F9-E00E-4682-B776-68B9E437829AQ35964560-7209599D-F0AB-4F25-AC33-D8805A4BD6EDQ36018577-75266DC2-FCF9-4331-8BC6-C54ACB14C469Q36083208-316D31F7-7FA6-4A4D-A96E-F85FD7CC9A15Q36620071-9E6EE862-AA53-4E39-B2B4-59D2478B663EQ36667074-629C26C1-DAC9-41D6-886C-F0D07D04965DQ36724345-C5818E9E-DCFE-4740-93E9-5DE991933DFFQ36933217-FEA9F388-0BE5-41F9-B7C6-C9DCADDB81B1Q36967288-793B09B7-1A29-4382-BB5F-27C2FB1A8837Q37144892-584A784E-351A-420E-8D25-BDBD1627DDDFQ37869258-FBF62580-8B53-4D21-9643-14F7FC8B01B9Q37970724-5DAF0A51-6BE8-4F99-85CA-B2AC68391286Q38791528-1DE0498A-6980-42C1-BF45-625683C8BD1DQ39067666-BF9407E7-F5E9-4815-8E4D-9DE27E172CFFQ39156752-ACBAF094-A969-4A17-9D54-18ADC4BDADE2Q40093553-54E5AB6B-277B-4512-AED1-27F18BBC5954Q40683242-66C1B644-AB7A-4131-9506-FCC3BB0777A6Q41000542-4149DE7C-8A23-4243-988D-D1168B6ACB16Q41466000-29372833-801B-4D2E-AFA7-318273294CB6Q41473712-C0F47F7C-1D41-43EB-A3EE-30E8DB13C3EFQ41831306-7CB72828-D590-4BE0-9FF7-34E4E9095FBDQ42846091-8B126F24-7243-4B12-909B-962E1B4F5736Q45258208-505CF652-6464-4256-947B-063BA55E5518Q45258847-97B6BE41-2AE5-4F6B-A354-048054C03D6BQ45375548-3C7CBEAF-27CC-424B-85F2-53D119C9C750Q45972156-F764834E-C854-4C2D-B68B-881341ED27E7Q47329892-D88925A3-087D-4E22-B6EE-8323ABA51C83Q47396324-898203D0-5471-45EB-A2ED-F499719C2A42
P2860
Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@en
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@nl
type
label
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@en
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@nl
prefLabel
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@en
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@nl
P2093
P356
P1476
Pharmacokinetics and tolerance ...... biotic, in healthy volunteers.
@en
P2093
Dennis J Stalker
Donald H Batts
Gail L Jungbluth
Nancy K Hopkins
P304
P356
10.1093/JAC/DKG180
P407
P577
2003-03-28T00:00:00Z